FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982361299> ?p ?o ?g. }

• W2982361299 endingPage "882" @default.
• W2982361299 startingPage "878" @default.
• W2982361299 abstract "Systems pharmacology integrates structural biological and pharmacological knowledge and experimental data, enabling dissection of organism and drug properties and providing excellent predictivity. The development of systems pharmacology models is a significant task requiring massive amounts of background information beyond individual trial data. The qualification of models needs repetitive demonstration of successful predictions. Open Systems Pharmacology is a community that develops, qualifies, and shares professional open source software tools and models in a collaborative open-science way. In recent years, systems pharmacology and its applications in pharmaceutical development have gained significant visibility and attention as an important pillar of model-informed drug (discovery and) development.1 Physiologically-based pharmacokinetics (PBPK) is just one of the many potential applications of systems pharmacology. Nevertheless, because of the generic relevance of pharmacokinetics in any pharmaceutical application, PBPK has seen the most rapid growth in terms of the number of organizations and scientists applying it and the published case studies. Regulatory use is documented in reviews of the European and US regulatory agencies2, 3 and has lately led both the US Food and Drug Administration (FDA)4 and European Medicines Agency5 to issue guidances for PBPK use. For some applications, PBPK has even become a recommended method (the FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee majority vote in support of the use of PBPK modeling for pediatric drug development, March 2012). In many regards, the slow development of PBPK from the early concepts in the 1930s6 over many decades to its accelerated uptake in some regulatory applications2, 3, 7 within just a few years is a striking example of the catalytic effects of a diverse scientific community (see Important Milestones of PBPK Modeling Supplement). In light of the success seen with some applications of PBPK, it is important to find effective ways to further grow more applications of systems pharmacology (a much broader concept than mechanistic pharmacokinetics modeling alone) to a level where their full potential in supporting pharmaceutical sciences and innovation is exploited. The development of any systems pharmacology model is a significant task requiring large amounts of high-quality background information. The qualification of models builds on the repetitive demonstration of successful predictions. Only in exceptional cases, individual researchers or organizations possess the resources and time for this undertaking. The integrative nature of system pharmacology, however, lends itself to an open-science approach where information, models, and software are jointly developed. To this end, building on 2 decades of experience with PBPK and system pharmacology modeling, we have established the Open Systems Pharmacology (OSP) community. OSP offers professional open access and open source software tools (PK-Sim/MoBi) and models via a platform for collaborative development and qualification. For any specific use such as first-in-man, drug–drug interactions, or kinetics in special populations, a series of overall successful prospective predictions is needed, and for none of the popular platforms has a general qualification scheme been established yet. Despite the expectations for model/platform qualifications as detailed in the guidances,4, 5 it is very likely that any of the individual stakeholders in the PBPK field (academics, software providers and consultancy firms, industry, regulatory agencies) will no longer be able to compile the evidence required for a convincing qualification of a given PBPK use in isolation. This is a simple fact even more so because the requirements cover the full scope from scientific content (e.g., clinical and preclinical data) to technical implementation (validation of computerized system) and documentation. Collaborative approaches are needed to compile the requested evidence in all these domains. The OSP's vision is to provide robust and reliable, easy-to-use modeling and simulation tools, processes, and models for pharmaceutical and other life-sciences applications. They shall be qualified and accepted by the scientific community representing academia, regulatory agencies, and industry and available and open to everyone (see OSP Links Supplement: Vision & Mission). The OSP community wants to provide a platform for joint development, review, and qualification; application of state-of-the-art tools for PBPK and systems pharmacology modeling; and an open library of models for application as well as method and tool qualification processes. Open systems pharmacology uses GitHub (GitHub, San Francisco, CA, USA) as its collaboration and exchange platform. From the release of version 7.0 in early 2017 onward, already eight releases of the formerly commercial OSP suite comprising PK-Sim (PBPK) and MoBi (general systems pharmacology modeling) have been published as open-source software (latest release 8.0; see OSP Links Supplement: Releases; GPLv2 license, see OSP Links Supplement: License). The OSP suite provides functionality for the full range of PBPK applications from physico-chemistry-based prediction models for all relevant (pre)clinical species to elaborated simulations for drug–drug interactions and special populations. The suite comprises functionalities for parameter identification, model qualification and automated reporting as well as interfaces to R (The R Project for Statistical Computing, www.R-project.org) and Matlab (The Mathworks, Natick, MA, USA) (Figure 2a; see OSP Links Supplement: OSP Suite). The continuous development of the software suite is run on GitHub and can be monitored by everyone in real time (see OSP Links Supplement: Continuous Development). Nightly builds of prerelease versions are available for all interested parties as is the source code. For sharing of data and PBPK and systems pharmacology models, dedicated repositories exist. The current model library includes PBPK models of individual drugs in particular drug–drug interaction victims and perpetrators and sophisticated systems pharmacology models. An expression database for proteins is also part of the OSP suite. Education and training of competent PBPK and systems pharmacology users is an important goal of the OSP community. A diverse group of knowledgeable users is the source of innovative ideas and new applications and workflows and creates a motivating environment. A series of videos and tutorials are already shared on GitHub that covers a broad range of topics from introductory lessons (e.g., understanding fundamental concepts of PBPK) to advanced applications (e.g., compliance with guidelines for model development and qualification; see OSP Links Supplement: Tutorials). Training curricula and teaching materials for use in graduate programs, industry, and regulatory environments are planned. For community members interested in providing training, the platform offers a natural “market place” for interaction with interested trainees. A less formal method of education and support is provided by the discussion forum. It supports OSP users in learning from and providing support to each other. It also serves as a match-making environment for formative assessment of ideas, models, and so on. When groups of community members intend to jointly develop new data sets, models, or tools, the GitHub platform also provides project management functionality facilitating collaborative work. OSP has been selected by several publicly funded projects as the provider of modeling and simulation tools and the technical platform for sharing of project results. Funding agencies of these projects include the German Ministry for Education and Research (BMBF), European Union, Bill & Melinda Gates Foundation9, and US FDA (see Acknowledgments). Because an important goal of OSP is regulatory-accepted qualification of PBPK and systems-pharmacology-based approaches, a strong emphasis of the OSP activities is on qualification efforts and the development of a framework for certification. The OSP community establishes best practices and fully transparent processes for qualification and software validation that will enable it to certify compliance with regulatory standards as a learned society (see Figure 2b, automated qualification as an example). The OSP management team is responsible for the development and maintenance of the OSP roadmap and the formal release of certified OSP suite versions, best practices, and the coordination of all community activities. Figure 1b sketches the constitution of the OSP community where three types of active roles are distinguished. The OSP management team is a project group of (Arbeitsgemeinschaft für Angewandte Humanpharmakologie (AGAH) e.V.) the association for applied human pharmacology (https://www.agah.eu). It is responsible for regular review, endorsement, and publication of the OSP development roadmap. The management team provides certification of the software platform, models, and other content such parameter databases and qualification processes. It releases certified platform versions. A sounding board supports the management team in scientific and technological matters. Community members are all active contributors to the development of OSP content. The OSP community also invites any interested party to use the provided content (software, models, etc.) because it benefits from widespread use and feedback provided via the OSP forum and other communication channels. This includes input and feedback from users and developers of commercial platforms. During the past decade, systems pharmacology and its PBPK applications have seen a rapid development from dominant academic use to widespread applications with regulatory relevance and high ethical and commercial impact. Although the concepts and tools have reached a considerable maturity, the next level of development, namely, the demonstration of regulatory acceptable qualification is a major challenge. To be successful, the PBPK and systems pharmacology community needs to collaborate. With OSP, we intend to lower hurdles and facilitate progress. OSP offers a framework for collaboration and open-access, open-source tools. The community organization aims to combine open science development with processes for review and certification from a learned society. We invite you to join us on www.open-systems-pharmacology.org. Funds for the creation of the article were provided by authors' organizations. On behalf of the community, the authors wish to thank US Food & Drug Administration (FDA) and European Union and German Ministry for Education and Research (BMBF) for providing funding for the further development of OSP. FDA: PBPK and Population Modeling Seamlessly Linked to Clinical Trial Simulation in an Open-Source Software Platform (Agreement RGF011519-A); European Union: Horizon 2020 Research and Innovation Programme–U-PGx consortium (Grant 668353), BMBF: OSMOSES consortium (Grant 031L0161A), nanoCELL consortium (Grant 03XP0196C), VISION consortium (Grant 031L0153A). All authors use Open Systems Pharmacology software, tools, or models in their professional roles. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W2982361299 created "2019-11-08" @default.
• W2982361299 creator A5002474275 @default.
• W2982361299 creator A5008544706 @default.
• W2982361299 creator A5019411028 @default.
• W2982361299 creator A5022371964 @default.
• W2982361299 creator A5027467292 @default.
• W2982361299 creator A5033927616 @default.
• W2982361299 creator A5035120478 @default.
• W2982361299 creator A5039437817 @default.
• W2982361299 creator A5040257468 @default.
• W2982361299 creator A5059002800 @default.
• W2982361299 creator A5061114113 @default.
• W2982361299 creator A5062673118 @default.
• W2982361299 creator A5062794983 @default.
• W2982361299 creator A5064514109 @default.
• W2982361299 creator A5067529021 @default.
• W2982361299 creator A5070310610 @default.
• W2982361299 creator A5080803089 @default.
• W2982361299 creator A5080845006 @default.
• W2982361299 creator A5089524539 @default.
• W2982361299 date "2019-11-12" @default.
• W2982361299 modified "2023-10-10" @default.
• W2982361299 title "Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences" @default.
• W2982361299 cites W1501922076 @default.
• W2982361299 cites W1550666041 @default.
• W2982361299 cites W1979930569 @default.
• W2982361299 cites W2024284722 @default.
• W2982361299 cites W2181278642 @default.
• W2982361299 cites W2892454342 @default.
• W2982361299 doi "https://doi.org/10.1002/psp4.12473" @default.
• W2982361299 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6930856" @default.
• W2982361299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31671256" @default.
• W2982361299 hasPublicationYear "2019" @default.
• W2982361299 type Work @default.
• W2982361299 sameAs 2982361299 @default.
• W2982361299 citedByCount "54" @default.
• W2982361299 countsByYear W29823612992020 @default.
• W2982361299 countsByYear W29823612992021 @default.
• W2982361299 countsByYear W29823612992022 @default.
• W2982361299 countsByYear W29823612992023 @default.
• W2982361299 crossrefType "journal-article" @default.
• W2982361299 hasAuthorship W2982361299A5002474275 @default.
• W2982361299 hasAuthorship W2982361299A5008544706 @default.
• W2982361299 hasAuthorship W2982361299A5019411028 @default.
• W2982361299 hasAuthorship W2982361299A5022371964 @default.
• W2982361299 hasAuthorship W2982361299A5027467292 @default.
• W2982361299 hasAuthorship W2982361299A5033927616 @default.
• W2982361299 hasAuthorship W2982361299A5035120478 @default.
• W2982361299 hasAuthorship W2982361299A5039437817 @default.
• W2982361299 hasAuthorship W2982361299A5040257468 @default.
• W2982361299 hasAuthorship W2982361299A5059002800 @default.
• W2982361299 hasAuthorship W2982361299A5061114113 @default.
• W2982361299 hasAuthorship W2982361299A5062673118 @default.
• W2982361299 hasAuthorship W2982361299A5062794983 @default.
• W2982361299 hasAuthorship W2982361299A5064514109 @default.
• W2982361299 hasAuthorship W2982361299A5067529021 @default.
• W2982361299 hasAuthorship W2982361299A5070310610 @default.
• W2982361299 hasAuthorship W2982361299A5080803089 @default.
• W2982361299 hasAuthorship W2982361299A5080845006 @default.
• W2982361299 hasAuthorship W2982361299A5089524539 @default.
• W2982361299 hasBestOaLocation W29823612991 @default.
• W2982361299 hasConcept C105795698 @default.
• W2982361299 hasConcept C136764020 @default.
• W2982361299 hasConcept C178855305 @default.
• W2982361299 hasConcept C199360897 @default.
• W2982361299 hasConcept C20136886 @default.
• W2982361299 hasConcept C2777904410 @default.
• W2982361299 hasConcept C2778149293 @default.
• W2982361299 hasConcept C2780535194 @default.
• W2982361299 hasConcept C3018397939 @default.
• W2982361299 hasConcept C33923547 @default.
• W2982361299 hasConcept C41008148 @default.
• W2982361299 hasConcept C67936045 @default.
• W2982361299 hasConcept C71924100 @default.
• W2982361299 hasConcept C98274493 @default.
• W2982361299 hasConceptScore W2982361299C105795698 @default.
• W2982361299 hasConceptScore W2982361299C136764020 @default.
• W2982361299 hasConceptScore W2982361299C178855305 @default.
• W2982361299 hasConceptScore W2982361299C199360897 @default.
• W2982361299 hasConceptScore W2982361299C20136886 @default.
• W2982361299 hasConceptScore W2982361299C2777904410 @default.
• W2982361299 hasConceptScore W2982361299C2778149293 @default.
• W2982361299 hasConceptScore W2982361299C2780535194 @default.
• W2982361299 hasConceptScore W2982361299C3018397939 @default.
• W2982361299 hasConceptScore W2982361299C33923547 @default.
• W2982361299 hasConceptScore W2982361299C41008148 @default.
• W2982361299 hasConceptScore W2982361299C67936045 @default.
• W2982361299 hasConceptScore W2982361299C71924100 @default.
• W2982361299 hasConceptScore W2982361299C98274493 @default.
• W2982361299 hasFunder F4320332999 @default.
• W2982361299 hasIssue "12" @default.
• W2982361299 hasLocation W29823612991 @default.
• W2982361299 hasLocation W29823612992 @default.
• W2982361299 hasLocation W29823612993 @default.
• W2982361299 hasLocation W29823612994 @default.
• W2982361299 hasLocation W29823612995 @default.
• W2982361299 hasLocation W29823612996 @default.

• next